CLINICAL_TRIALS
trial_result
· 2014-12-31
Clinical Trial Update: Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites [Phase 1]
Summary
A Phase 1 pharmacokinetic study assessing single-dose and steady-state exposure of BIA 2-093 and its metabolites in the context of epilepsy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2014-12-31